Publication
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker
| dc.contributor.author | Aguiar, Pedro N., Jr. | |
| dc.contributor.author | Santoro, Ilka Lopes | |
| dc.contributor.author | Tadokoro, Hakaru | |
| dc.contributor.author | Lopes, Gilberto de Lima | |
| dc.contributor.author | Filardi, Bruno Andraus | |
| dc.contributor.author | Oliveira, Pedro | |
| dc.contributor.author | Castelo-Branco, Pedro | |
| dc.contributor.author | Mountzios, Giannis | |
| dc.contributor.author | de Mello, Ramon Andrade | |
| dc.date.accessioned | 2017-04-07T15:56:09Z | |
| dc.date.available | 2017-04-07T15:56:09Z | |
| dc.date.issued | 2016-09 | |
| dc.description.abstract | Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit. | |
| dc.identifier.doi | 10.2217/imt-2016-0032 | |
| dc.identifier.issn | 1750-743X | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/9333 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.relation.isbasedon | WOS:000380819800006 | |
| dc.title | A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker | |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1019 | |
| oaire.citation.issue | 9 | |
| oaire.citation.startPage | 1011 | |
| oaire.citation.title | Immunotherapy | |
| oaire.citation.volume | 8 | |
| person.familyName | Castelo-Branco | |
| person.familyName | de Mello | |
| person.givenName | Pedro | |
| person.givenName | Ramon Andrade | |
| person.identifier.ciencia-id | E015-7F8F-5CA1 | |
| person.identifier.orcid | 0000-0002-3453-3978 | |
| person.identifier.orcid | 0000-0002-9640-4573 | |
| rcaap.rights | restrictedAccess | |
| rcaap.type | article | |
| relation.isAuthorOfPublication | bb25b5ad-1769-42be-a7d3-8fe76215aa23 | |
| relation.isAuthorOfPublication | 53ee625f-c5c3-468b-85bb-4cef5ad36928 | |
| relation.isAuthorOfPublication.latestForDiscovery | bb25b5ad-1769-42be-a7d3-8fe76215aa23 |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- aguiar2016.pdf
- Size:
- 2.21 MB
- Format:
- Adobe Portable Document Format